Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Ovarian Neoplasms

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 23 articles:
HTML format



Single Articles


    August 2025
  1. MAJIDI A, Rinaldi S, Biessy C, Vozar B, et al
    Thyroid hormones and epithelial ovarian cancer risk and survival: results from the EPIC study.
    J Natl Cancer Inst. 2025 Aug 14:djaf222. doi: 10.1093.
    PubMed     Abstract available


  2. JONES RR, Madrigal JM, Medgyesi DN, Fisher JA, et al
    Serum concentrations of per- and polyfluoroalkyl substances and risk of ovarian cancer.
    J Natl Cancer Inst. 2025 Aug 1:djaf204. doi: 10.1093.
    PubMed     Abstract available


    April 2025
  3. LI S, Madanat-Harjuoja L, Leslie G, Barnes DR, et al
    Childhood, adolescent, and young adulthood cancer risk in BRCA1 or BRCA2 pathogenic variant carriers.
    J Natl Cancer Inst. 2025;117:728-736.
    PubMed     Abstract available


  4. STROOT IAS, Bart J, Hollema H, Wagner MM, et al
    High-grade serous carcinoma occurring after risk-reducing salpingo-oophorectomy in BRCA1/2 germline pathogenic variant carriers.
    J Natl Cancer Inst. 2025;117:719-727.
    PubMed     Abstract available


    February 2025
  5. LEHRER S
    Re: Timing of depression in relation to risk of ovarian cancer.
    J Natl Cancer Inst. 2025 Feb 25:djaf043. doi: 10.1093.
    PubMed    


    January 2025
  6. ROBERTS AL, Townsend MK, Chibnik LB, Kubzansky LD, et al
    Timing of depression in relation to risk of ovarian cancer.
    J Natl Cancer Inst. 2025 Jan 2:djae348. doi: 10.1093.
    PubMed     Abstract available


    December 2024
  7. EVANS DG, Flaum N, Crosbie EJ
    High-grade serous ovarian cancer after bilateral salpingo-oophorectomy.
    J Natl Cancer Inst. 2024 Dec 31:djae328. doi: 10.1093.
    PubMed    


  8. ELZE L, van der Post RS, Vos JR, Mensenkamp AR, et al
    Genomic instability in non-breast or ovarian malignancies of individuals with germline pathogenic variants in BRCA1/2.
    J Natl Cancer Inst. 2024;116:1904-1913.
    PubMed     Abstract available


    November 2024
  9. NAROD SA, Gronwald J, Karlan B, Moller P, et al
    Incidence of peritoneal cancer after oophorectomy among BRCA1 and BRCA2 mutation carriers.
    J Natl Cancer Inst. 2024;116:1753-1760.
    PubMed     Abstract available


    October 2024
  10. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1675-1682.
    PubMed     Abstract available


    August 2024
  11. FOULKES WD, Polak P
    Probing the relevance of BRCA1 and BRCA2 germline pathogenic variants beyond breast and ovarian cancer.
    J Natl Cancer Inst. 2024 Aug 22:djae184. doi: 10.1093.
    PubMed    


  12. MYERS ER
    Reducing ovarian cancer mortality through screening: an impossible dream?
    J Natl Cancer Inst. 2024 Aug 12:djae175. doi: 10.1093.
    PubMed    


  13. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1280-1287.
    PubMed     Abstract available


    July 2024
  14. ISHIZAWA S, Niu J, Tammemagi MC, Irajizad E, et al
    Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework.
    J Natl Cancer Inst. 2024 Jul 23:djae145. doi: 10.1093.
    PubMed     Abstract available


  15. ZHENG G, Baandrup L, Wang J, Hertzum-Larsen R, et al
    Ovarian cancer risk factors in relation to family history.
    J Natl Cancer Inst. 2024 Jul 4:djae164. doi: 10.1093.
    PubMed     Abstract available


    June 2024
  16. BAKER SG, Etzioni R
    Prediagnostic evaluation of multicancer detection tests: design and analysis considerations.
    J Natl Cancer Inst. 2024;116:795-799.
    PubMed     Abstract available


    May 2024
  17. DAVIS EW, Attwood K, Prunier J, Paragh G, et al
    The association of body composition phenotypes before chemotherapy with epithelial ovarian cancer mortality.
    J Natl Cancer Inst. 2024 May 28:djae112. doi: 10.1093.
    PubMed     Abstract available


    February 2024
  18. CAO A, Esserman DA, Cartmel B, Irwin ML, et al
    Association between diet quality and ovarian cancer risk and survival.
    J Natl Cancer Inst. 2024 Feb 23:djae040. doi: 10.1093.
    PubMed     Abstract available


    July 2023
  19. PHUNG MT, Lee AW, McLean K, Anton-Culver H, et al
    A framework for assessing interactions for risk stratification models: the example of ovarian cancer.
    J Natl Cancer Inst. 2023 Jul 12:djad137. doi: 10.1093.
    PubMed     Abstract available


    June 2023
  20. HURWITZ LM, Dogbe N, Hughes Barry K, Koutros S, et al
    Obesity and prostate cancer screening, incidence, and mortality in the PLCO Cancer Screening Trial.
    J Natl Cancer Inst. 2023 Jun 29:djad113. doi: 10.1093.
    PubMed     Abstract available


  21. LI S, Nguyen-Dumont T, Southey MC, Hopper JL, et al
    RE: Heterozygous BRCA1 and BRCA2 and mismatch repair gene pathogenic variants in children and adolescents with cancer.
    J Natl Cancer Inst. 2023;115:757-759.
    PubMed    


    May 2023
  22. SHI J, Kraft P, Rosner BA, Benavente Y, et al
    Risk prediction models for endometrial cancer: development and validation in an international consortium.
    J Natl Cancer Inst. 2023;115:552-559.
    PubMed     Abstract available


    April 2023
  23. GUPTA S, Hanna PE, Ouyang T, Yamada KS, et al
    Kidney Function in Patients with Ovarian Cancer Treated with Poly (ADP-ribose) polymerase (PARP) Inhibitors.
    J Natl Cancer Inst. 2023 Apr 19:djad070. doi: 10.1093.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.